Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones
- 22 May 2001
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 61 (12) , 1509-1516
- https://doi.org/10.1016/s0006-2952(01)00631-1
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Immunological Quantitation of DT‐Diaphorase in Carcinoma Cell Lines and Clinical Colon Cancers: Advanced Tumors Express Greater Levels of DT‐DiaphoraseJapanese Journal of Cancer Research, 1998
- The mitomycin bioreductive antitumor agents: Cross-linking and alkylation of DNA as the molecular basis of their activityPharmacology & Therapeutics, 1997
- Re-evaluation of the molecular pharmacology of mitomycin CEuropean Journal Of Cancer, 1995
- DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?British Journal of Cancer, 1995
- The Case for Mitomycin in Non-Small Cell Lung CancerOncology, 1993
- Bioreductive activation of mitomycin C by DT-diaphoraseBiochemistry, 1992
- High levels of expression of the NAD(P)H:Quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same originBiochemical Pharmacology, 1991
- Cytosolic NAD(P)H:(Quinone‐acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcoholInternational Journal of Cancer, 1990
- Metabolic activation of mitomycin C by liver microsomes and nucleiBiochemical Pharmacology, 1982
- Mitomycin C: a reviewCancer Treatment Reviews, 1976